Navigation Links
Resverlogix's Success in Inflammation Program Results in 2 Patents Filed
Date:5/19/2009 

    Novel small molecules illustrate potential cost effective approach for
    rheumatoid arthritis

    TSX Exchange Symbol: RVX

CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases. Two new patent applications have been filed for novel compounds and their use in regulating inflammatory markers. Inflammatory markers are proteins generated by the body during periods of inflammation. These patents were filed based on the successful results demonstrated in numerous preclinical studies across several disease areas. The particular results achieved in the collagen induced arthritis (CIA) model in rats demonstrated that Resverlogix's proprietary molecules markedly reduced inflammation while improving mobility of arthritic animals.

"Resverlogix's R&D program has made significant strides this past year," said Donald J. McCaffrey, President & CEO of Resverlogix. "The Company has identified several molecules that have the potential for disease modifying effects in inflammatory disorders such as rheumatoid arthritis. Resverlogix's R&D team is continuing to examine the various disease indications in inflammation which would have the greatest potential impact for both patients and payer groups," continued McCaffrey.

A significant unmet medical need exists for safe, effective and economical therapies for specific inflammation markets. For example, a small molecular drug for rheumatoid arthritis is estimated to range in price from US $180 - US $6000 per person per annum. A biologic, or large molecule drug, can cost in the order of US $13,000 - US $30,000 per patient per annum. In 2007, the global market for rheumatoid arthritis alone was estimated to be in excess of US $11 billion a year and is expected to
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
2. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
3. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
8. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
9. Addiction Treatment Finds Success Treating Brain Deficiencies through the Belly
10. Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
11. Sundia MediTech and Xcovery Announce Big Success in Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
(Date:5/23/2013)... 23, 2013  Saddleback Memorial Medical Center in ... first hospital on the West Coast to perform a ... option provides women with a state-of-the-art, minimally invasive approach ... Winter , M.D., a highly regarded ... director of minimally invasive surgery at Saddleback Memorial, led ...
(Date:5/23/2013)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... immune therapies for solid tumor cancers, announced today that ... Society Of Clinical Oncology (ASCO) meeting in ... immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... conference focused on clinical treatment of cancer, with attendance ...
(Date:5/23/2013)... Korea , May 23, 2013 ... SillaJen, Inc., a private biotherapeutics and contract research ... biological products for cancer, announced today a publication ... patients treated with the oncolytic and immunotherapeutic vaccinia ... This research was published in the May 15 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Oct. 27 eBioscience Corporation today announced that ... Bender MedSystems GmbH in an all cash transaction. ... high profile immunology and oncology products including the ... life sciences and diagnostics markets. , "Bender MedSystems ...
... Medivation, Inc. (Nasdaq: MDVN) today announced that it will ... October 27, to discuss partnering plans for MDV3100, Medivation,s investigational ... treatment of prostate cancer. , Teleconference/Webcast Details ... October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ...
... Champions Biotechnology, Inc. (OTC Bulletin ... aimed at accelerating the development and enhancing the value ... Biotech Oncology Research & Development, a Division of Janssen ... oncology therapeutic in Champions, Biomerk Tumorgraft(TM) platform. ...
Cached Biology Technology:eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations 2eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations 3Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 2Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 3
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
(Date:5/23/2013)... undergo surgery or harsh treatments because science fails ... forms of the disease. Researchers at Case Western ... developing technology that allows patients to safely choose ... or take drastic measures. , The project is ... of biomedical engineering at Case Western Reserve and ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... a cabbage-eating moth may one day provide a safer, target-specific ... , They compared the ability of the four best-characterized jumping ... and produce a desired change, such as making the cell ... piggyBac transposon was five to 10 times better than the ...
... the largest HIV/AIDS therapy studies conducted to date ... therapy more than doubles the risk of AIDS ... the Mailman School of Public Health and Harlem ... known as Strategies for Management of Anti-Retroviral Therapies, ...
... may be placing their unborn children at increased risk ... study of construction workers in the Netherlands, conducted in ... links low birth weight and birth defects to paternal, ... and cleansers. , The study, although preliminary in its ...
Cached Biology News:Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3Study shows interruption of antiretroviral therapy increases risk of disease and death 2Study shows interruption of antiretroviral therapy increases risk of disease and death 3Solvent exposure linked to birth defects in babies of male painters 2
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Request Info...
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
Biology Products: